<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669939</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-0154</org_study_id>
    <nct_id>NCT03669939</nct_id>
  </id_info>
  <brief_title>Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations</brief_title>
  <acronym>TOWER</acronym>
  <official_title>Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations: Implementing the Centers for Disease Control Guideline (CDC) Guideline in the Primary Care HIV Clinic.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The New York Academy of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching plan for TOWER is to develop and test an algorithmic version of the Center
      for Disease Control Guidelines (CDCG) tailored for a specific primary care setting, the HIV
      primary care clinic. This CDCG intervention incorporates communication and implementation
      strategies tailored for the HIV primary care setting, and enabled with technology (an app for
      use by patients and EMR tools for providers).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      However, according to a 2014 AHRQ report, there have been no studies evaluating the
      effectiveness of any prescription opioid risk mitigation strategies. Furthermore, due to
      ambiguity in some of the CDCG recommendations and the challenging nature of the
      patient-provider opioid conversation, the success of the CDCG may hinge on the manner in
      which it is implemented in individual care settings. Thus it is unclear what the true effect
      of the CDCG will be. The investigators believe that for the CDCG to have the greatest
      likelihood of achieving its goals of improving prescription opioid safety without causing
      unintended effects (e.g. exacerbation of pain, disruption of other aspects of care), its
      recommendations will need to be skillfully communicated. Furthermore, because of this &quot;human
      element&quot;and other sources of variability, documenting the effectiveness of the CDCG will
      require standardization of implementation. The overarching plan for TOWER is to develop and
      test an algorithmic version of the CDCG tailored for a specific primary care setting, the HIV
      primary care clinic. This CDCG intervention incorporates communication and implementation
      strategies tailored for the HIV primary care setting, and enabled with technology (an app for
      use by patients and EMR tools for providers). Achieving this goal has involved soliciting
      input from the HIV community using the method of Public Deliberation (PD) in the setting of
      two Citizen' s Panels, each with ~22 HIV-infected participants and lasting one day; and using
      the information obtained from the deliberative process to inform the development of the CDCG
      intervention. The investigators now plan to test the CDCG intervention for feasibility.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eligible PCPs who successfully complete randomization</measure>
    <time_frame>18 months</time_frame>
    <description>Feasibility of recruitment and randomization of PCPs, reflected by the proportion of eligible PCPs who successfully complete randomization (where the denominator is the total number of PCPs offered participation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of items in the CDCG intervention which were adhered to</measure>
    <time_frame>18 months</time_frame>
    <description>Maintenance of intervention fidelity will be ascertained using the audiotaped data from the clinic visits, and will be described as the percentage of items in the CDCG intervention which were adhered to.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Standard of Care</measure>
    <time_frame>18 months</time_frame>
    <description>Per the CDC guideline (CDCG) for prescribing opioids in general primary care settings, there are 12 recommendations providers must follow in order to reduce prescription opioid-related harms while maintaining pain control and function. In order to monitor providers' adherence to the guideline and to establish appropriateness of &quot;usual care&quot;, within the control arm, we will implement the CDCG Adherence Assessment Tool. The CDCG Adherence tool will score patients' EMR notes and will consist of 10-items relevant to the 12 recommendations outlined in the CDCG. If the CDCG recommendations have been denoted in the EMR note, each item will receive points based on a 1-2 numeric scale (max of 16 points). All clinical visits completed during the duration of the study will be scored. A higher number indicating a favorable outcome of adherence to the CDCG guideline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary Outcome Measure determination</measure>
    <time_frame>18 months</time_frame>
    <description>The best choice of a primary outcome measure for future studies.</description>
  </other_outcome>
  <other_outcome>
    <measure>CDCG Adherence Assessment Tool</measure>
    <time_frame>18 months</time_frame>
    <description>Two tools will be provided to Intervention providers, an Opioid Managing-app (OM-app) and an EMR note template. The acceptability of the OM-app and EMR tool within the clinical setting will be measured. The OM-app was designed to help collect data needed by the PCP to follow the CDC guideline. The OM-app will contact patients once daily with a link which will take them to a series of questions relevant to their pain management. The app will be responsible for aggregating this data into a report form that the PCP can utilize to facilitate a discussion with the patient and to populate an EMR progress note. The EMR note template will be provided to intervention providers in order to import data collected from the app into a patient's EMR during clinic visits. As with the control arm, the CDCG Adherence Assessment Tool will be implemented which will score patients' EMR notes on a 1-2 numeric scale (max of 16 points). A higher number indicating a favorable outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Current Opioid Misuse Measure (COMM)</measure>
    <time_frame>18 months</time_frame>
    <description>17-item, each scored 0 (never) to 4 (very often) with total scale from 0 - 68, higher score indicating more opioid misuse</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-Reported Misuse, Abuse, and Diversion (SR-MAD)</measure>
    <time_frame>18 months</time_frame>
    <description>Self-Reported Misuse, Abuse and Diversion of Prescription Opioids (SR-MAD) instrument consists of 18 self-report items 0-10 numerical rating scale. Total scale from 0 to 180, with higher score indicating worse outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>18 months</time_frame>
    <description>Brief Pain Inventory (BPI) is a 9-item instrument with total score from 0 to 10, with higher score indicating worse outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>18 months</time_frame>
    <description>14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms). Scores for the entire scale is 0 to 42, with higher score indicating more distress.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trust in Provider Scale (TIPS)</measure>
    <time_frame>18 months</time_frame>
    <description>11-items scale scored on a 5-point likert scale from 1 (strongly disagree) to 5 (strongly agree). A 52 Freburger et al summary measure of trust is obtained by taking the unweighted mean of the responses to the 11 questions and transforming that value to a 0-100 scale. Higher scores reflect greater trust.</description>
  </other_outcome>
  <other_outcome>
    <measure>HIV Stigma Scale (HSS)</measure>
    <time_frame>18 months</time_frame>
    <description>40-items using a 4 point likert scale 1 (strongly disagree) to 4 (strongly agree), with full scale from 40 to 160. Higher score indicates poorer outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Brief Perceived Ethnic Discrimination Questionnaire-Community Version (BPEDQ-CV)</measure>
    <time_frame>18 months</time_frame>
    <description>17-item scale on a summed average likert-type scale from 1 (never happened) to 5 (happened very often). Higher score indicated perception of discrimination.</description>
  </other_outcome>
  <other_outcome>
    <measure>Internalized Stigma of Chronic Pain (ISCP)</measure>
    <time_frame>18 months</time_frame>
    <description>Sum average score on 4-point Likert-type scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher score indicates more stigma of chronic pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Consumer Assessment of Healthcare Providers and System (CAHPSÂ®) Clinician &amp; Group Survey (CG-CAHPS)</measure>
    <time_frame>18 months</time_frame>
    <description>Composite score converted to numerical scale from 0 (never) to 100 (always). and one overall rating of the doctor on a scale from 0 to 10, with higher score showing a more favorable outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Opioid Therapy PROVIDER Survey</measure>
    <time_frame>18 months</time_frame>
    <description>10 question survey, sum average score on a 5-point likert scale 1 (strongly agree) to 5 (strongly disagree)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intervention provider post- survey</measure>
    <time_frame>18 months</time_frame>
    <description>6 question survey, intended for provider participants who have been randomized into the intervention arm. The survey includes a 5-point Likert-scale (5=strongly agree, 4=agree, 3=neutral, 2=disagree, 1=strongly disagree) with a high sum average indicating a satisfactory outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified ACTG Adherence</measure>
    <time_frame>18 months</time_frame>
    <description>A self-reported questionnaire comprised of 8 items. Only item #4 will be used as a percentage of their HIV medication intake, on a scale from 0-100%. . A higher percentage indicating a favorable outcome..</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative Analgesic Questionnaire (QAQ)</measure>
    <time_frame>18 months</time_frame>
    <description>Tool for quantifying how much pain meds a patient is taking, by calculating the total weekly doses, the QAQ (&quot;as reported&quot;), and comparing them to the regimen score previously established by physicians who actively treat chronic pain. Regimens are rated on scale from 1 (small amount of meds) to 5 (large amt of meds). 1 QAQ point is assign for taking any opioids at all, &amp; an additional point assign for every equivalent of 100 mg of oral morphine used per week (1-99 mg = 1 pt; 100-199 = 2 pts, etc.). For all other oral meds, 1 point for taking the meds at all, &amp; an additional point for each 25% of the maximum dose taken (1-24% = 1 pt; 25-49% = 2 points, etc.). For topicals, 1 point for each topical reports using regardless of dose or frequency. No upper limit to the amt of QAQ points a patient may accrue. The lowest number of QAQ is 0=no medication. A higher discrepancy between the sum average of QAQ points and &quot;as prescribed&quot; points will indicate a lower adherence rate.</description>
  </other_outcome>
  <other_outcome>
    <measure>TOWER Post Clinic Visit Interview</measure>
    <time_frame>18 months</time_frame>
    <description>This is an 18 item questionnaire of the patients experience after a clinical session with their provider. There are 2 scores, one score will be a sum average on a scale from 0-6 for questions 1-6. The second score will be a sum average on a scale from 0-50 for questions 8-12. A higher scored indicating a favorable outcome.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Disease</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Communication strategy</arm_group_label>
    <description>Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <description>Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Communication Strategy</intervention_name>
    <description>Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.</description>
    <arm_group_label>Communication strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>The standard information about the CDC Guidelines and no other information that is available through the study.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Providers who treat HIV patients in the Institute of Advanced Medicine
        Institute at Mount Sinai Health System
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Attending physician or advance practice provider in one of the Institute of Advanced
             Medicine (IAM) clinics

          -  Designated PCP for at least 5 patients to whom he/she prescribes opioids

          -  Willing and able to adhere to study procedures including randomization, and refraining
             from discussion of study procedures with other clinical staff or patients

        Exclusion Criteria:

          -  Unwillingness to undergo randomization

          -  Plans to leave IAM within the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Robinson-Papp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Catherine George, PhD</last_name>
    <phone>212-241-0784</phone>
    <email>mary-catherine.george@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Robinson-Papp, MD</last_name>
    <phone>212-241-8390</phone>
    <email>jessica.robinson-papp@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jessica Robinson-Papp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Center for Disease Control Guidelines</keyword>
  <keyword>Opioids for chronic pain</keyword>
  <keyword>communication strategies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Clinical information that is relevant to the provider or patient</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

